CELLULOSIC-BASED INTERFERENCE DOMAIN FOR AN ANALYTE SENSOR

• US 20100121169A1
• Filed: 01/21/2010
• Published: 05/13/2010
• Est. Priority Date: 04/08/2005
• Status: Abandoned Application

• Current Assignee: DexCom Incorporated
• Original Assignee: DexCom Incorporated
• Inventors: Tran, Olivia Janet, Nicholas, Melissa, Ha, Victor, Campbell, Rebecca A., Boock, Robert, Petisce, James R., Woo, Kum Ming
• Application Number:
  US12/691,617
• Publication Number:
  US 20100121169A1
• Time in Patent Office: Days
• US Class Current: 600/347
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14865 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
• CPC Class Codes: A61B 5/6833 Adhesive patches
• CPC Class Codes: A61B 5/6848 Needles
• CPC Class Codes: A61B 5/6849 in combination with a needle set
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present invention relates generally to devices for measuring an analyte in a host. More particularly, the present invention relates to devices for measurement of glucose in a host that incorporate a cellulosic-based interference domain.

Claims

1. An implantable device for continuous in vivo measurement of a glucose concentration in a host, the implantable device comprising:

a sensing region operatively connected to electronic circuitry configured to continuously generate, over a period of at least about 3 days, a signal associated with an in vivo concentration of glucose in a host; and

a membrane located over the sensing region, wherein the membrane comprises a first domain configured to control a flux of glucose and oxygen therethrough, a second domain comprising an enzyme configured to react with glucose, and a third domain configured to substantially reduce a flux of at least one interferent therethrough, wherein the third domain comprises at least one cellulosic derivative;

wherein the implantable device is configured to reduce, while immersed in a solution with an acetaminophen concentration of about 6.5 mg/dL, an equivalent glucose response signal associated with acetaminophen to less than about 30 mg/dL.

2. The implantable device of claim 1, wherein the equivalent glucose response signal associated with acetaminophen is less than about 20 mg/dL.

3. The implantable device of claim 1, wherein the equivalent glucose response signal associated with acetaminophen is less than about 10 mg/dL.

4. The implantable device of claim 1, wherein the implantable device is configured to reduce, while immersed in a solution with an ascorbic acid concentration of about 3.8 mg/dL, an equivalent glucose response signal associated with ascorbic acid to less than about 30 mg/dL.

5. The implantable device of claim 4, wherein the equivalent glucose response signal associated with ascorbic acid to less than about 20 mg/dL.

6. The implantable device of claim 4, wherein the equivalent glucose response signal associated with ascorbic acid to less than about 10 mg/dL.

7. The implantable device of claim 4, wherein the equivalent glucose response signal associated with ascorbic acid is substantially about 0 mg/dL.

9. The implantable device of claim 1, wherein the third domain comprises cellulose acetate.

10. The implantable device of claim 9, wherein the third domain further comprises cellulose acetate butyrate.

11. The implantable device of claim 1, wherein the first domain is disposed more distally from the sensing region than the second domain.

12. The implantable device of claim 11, wherein the second domain is disposed more distally from the sensing region than the third domain.

13. The implantable device of claim 1, wherein the third domain comprises crosslinked polymers.

14. The implantable device of claim 1, wherein the first domain comprises a hydrophobic-hydrophilic copolymer.

15. The implantable device of claim 1, wherein the first domain comprises a fluorocarbon-based material.

16. The implantable device of claim 1, wherein the first domain comprises a copolymer comprising a polyurethane segment and a silicone segment.

17. The implantable device of claim 1, wherein the implantable device is configured to be implanted subcutaneously.

18. The implantable device of claim 1, wherein the implantable device is configured to be implanted transdermally.

19. The implantable device of claim 1, wherein the implantable device is configured to be implanted intravascularly.

20. The implantable device of claim 1, wherein the period of at least about 3 days is a period of at least about 5 days.

21. The implantable device of claim 1, wherein the period of at least about 3 days is a period of at least about 7 days.

22. The implantable device of claim 1, wherein the period of at least about 3 days is a period of at least about 10 days.

8. The implantable device of Claim, wherein the implantable device is configured to reduce, while immersed in a solution with a uric acid concentration of about 9.5 mg/dL, an equivalent glucose response signal associated with uric acid to less than about 30 mg/dL.